RIGHT for CPM checklist（English Version）


The RIGHT for CPM checklist
7 sections, 23 topics and 51 Items		Assessment	Page(s)	Note(s)
Section/topic	No./Item
Basic information
Title/subtitle
1a	Identify the report as a guideline, that is, with “guideline(s)” or “recommendation(s)” in the title.	Yes No Unclear
1b	Describe the year of publication of the guideline.	Yes No Unclear
S1	Identify the document as a Chinese patent medicine guideline in the title.	Yes No Unclear
R1c	Describe the focus of the guideline, such as treatment, prevention, rehabilitation, or nursing care.	Yes No Unclear
Executive summary
2	Provide a summary of the recommendations contained in the guideline.	Yes No Unclear
Abbreviations and acronyms
3	Define new or key terms, and provide a list of abbreviations and acronyms if applicable.	Yes No Unclear
Corresponding developer
4	Identify at least 1 corresponding developer or author who can be contacted about the guideline.	Yes No Unclear
Registration information
S2	Indicate whether the guideline has been registered, and if so, provide details about the registration platform and approval number.	Yes No Unclear
Background
Brief description of the health problem(s)
5	Describe the basic epidemiology of the problem, such as the prevalence/incidence, morbidity, mortality, and burden (including financial) resulting from the problem.	Yes No Unclear
S3	Describe the categories, causes, pathogenesis, diagnostic points, and syndrome classification of diseases from the perspective of Chinese medicine.	Yes No Unclear
S4	Describe the current state of use of Chinese patent medicines in treating the disease.	Yes No Unclear
S5	Describe the advantages and disadvantages of Chinese patent medicines in treating the disease.	Yes No Unclear
S6	Describe the necessity or significance of developing a guideline for Chinese patent medicine use for this topic.	Yes No Unclear
Aim(s) of the guideline and specific objectives
6	Describe the aim(s) of the guideline and specific objectives, such as improvements in health indicators (e.g., mortality and disease prevalence), quality of life, or cost savings.	Yes No Unclear
Target population(s)
7a	Describe the primary population(s) that is affected by the recommendation(s) in the guideline.	Yes No Unclear
7b	Describe any subgroups that are given special consideration in the guideline.	Yes No Unclear
End users and settings
8a	Describe the intended primary users of the guideline (such as primary care providers, clinical specialists, public health practitioners, program managers, and policymakers) and other potential users of the guideline.	Yes No Unclear
8b	Describe the setting(s) for which the guideline is intended, such as primary care, low- and middle-income countries, or inpatient facilities.	Yes No Unclear
Guideline development groups
R9a	Describe how all contributors to the guideline development were selected and their roles and responsibilities (e.g., steering group, guideline panel, external reviewers, systematic review team, and methodologists). In addition to clinical TCM experts, the guideline panel should contain at least one clinical expert in Western medicine and one expert in clinical pharmacy.	Yes No Unclear
9b	List all individuals involved in developing the guideline, including their title, role(s), and institutional affiliation(s).	Yes No Unclear
Evidence
Health care questions
10a	State the key questions that were the basis for the recommendations in PICO (population, intervention, comparator, and outcome) or another format as appropriate.	Yes No Unclear
S7	Describe the sources of Chinese patent medicines to be included in the guideline (such as other guidelines, pharmacopoeia, essential medicine lists, medical insurance catalogue, etc.).	Yes No Unclear
S8	Describe the basis (methods and results) for selecting the Chinese patent medicines in the guideline.	Yes No Unclear
10b	Indicate how the outcomes were selected and sorted.	Yes No Unclear
Systematic reviews
11a	Indicate whether the guideline is based on new systematic reviews done specifically for this guideline or whether existing systematic reviews were used.	Yes No Unclear
11b	If the guideline developers used existing systematic reviews, reference these and describe how those reviews were identified and assessed (provide the search strategies and the selection criteria, and describe how the risk of bias was evaluated) and whether they were updated.	Yes No Unclear
Assessment of the certainty of the body of evidence
12	Describe the approach used to assess the certainty of the body of evidence.	Yes No Unclear
Recommendations
Recommendations
13a	Provide clear, precise, and actionable recommendations.	Yes No Unclear
S9	Describe details about the target disease, including disease stages (or levels/grades) and severity.	Yes No Unclear
S10	Describe the symptoms and syndromes of the target disease treated with Chinese patent medicines.	Yes No Unclear
13b	Present separate recommendations for important subgroups if the evidence suggests that there are important differences in factors influencing recommendations, particularly the balance of benefits and harms across subgroups.	Yes No Unclear
13c	Indicate the strength of recommendations and the certainty of the supporting evidence.	Yes No Unclear
Rationale/explanation for recommendations
14a	Describe whether values and preferences of the target population(s) were considered in the formulation of each recommendation. If yes, describe the approaches and methods used to elicit or identify these values and preferences. If values and preferences were not considered, provide an explanation.	Yes No Unclear
14b	Describe whether cost and resource implications were considered in the formulation of recommendations. If yes, describe the specific approaches and methods used (such as cost-effectiveness analysis) and summarize the results. If resource issues were not considered, provide an explanation.	Yes No Unclear
14c	Describe other factors taken into consideration when formulating the recommendations, such as equity, feasibility, and acceptability.	Yes No Unclear
S11	Describe the composition, source or origin of the recommended Chinese patent medicines (if applicable).	Yes No Unclear
S12	Describe the preparation formula, usage and dosage of the recommended Chinese patent medicines.	Yes No Unclear
S13	Describe the administration route of the recommended Chinese patent medicines (such as oral administration, external use, inhalation, etc.).	Yes No Unclear
S14	Describe the course or duration of treatment with the recommended Chinese patent medicines.	Yes No Unclear
S15	Provide known safety information for the recommended Chinese patent medicines and any precautions or considerations for special populations, such as children, the elderly, pregnant women, individuals with allergies, etc.	Yes No Unclear
S16	If the recommended Chinese patent medicines need to be used in combination with other medications, describe the name(s) of these medications (if applicable).	Yes No Unclear
Evidence to decision processes
15	Describe the processes and approaches used by the guideline development group to make decisions, particularly the formulation of recommendations (such as how consensus was defined and achieved and whether voting was used).	Yes No Unclear
Review and quality assurance
External review
16	Indicate whether the draft guideline underwent independent review and, if so, how this was executed and the comments considered and addressed.	Yes No Unclear
Quality assurance
17	Indicate whether the guideline was subjected to a quality assurance process. If yes, describe the process.	Yes No Unclear
Funding and declaration and management of interests
Funding source(s) and role(s) of the funder
18a	Describe the specific sources of funding for all stages of guideline development.	Yes No Unclear
18b	Describe the role of funder(s) in the different stages of guideline development and in the dissemination and implementation of the recommendations.	Yes No Unclear
Declaration and management of interests
19a	Describe what types of conflicts (financial and nonfinancial) were relevant to guideline development.	Yes No Unclear
19b	Describe how conflicts of interest were evaluated and managed and how users of the guideline can access the declarations.	Yes No Unclear
Other information
Access
20	Describe where the guideline, its appendices, and other related documents can be accessed.	Yes No Unclear
Suggestions for further research
21	Describe the gaps in the evidence and/or provide suggestions for future research.	Yes No Unclear
Limitations of the guideline
22	Describe any limitations in the guideline development process (such as the development groups were not multidisciplinary or patients' values and preferences were not sought), and indicate how these limitations might have affected the validity of the recommendations.	Yes No Unclear
Reference: Li X, Huang L, Wang L, Jin X, Zhou Q, Ma Y, Wang Q, Wang T, Hu X, Ye D, Mao Y, Xie Z, Chen Y, Wen C. The reporting checklist for Chinese patent medicine guidelines: RIGHT for CPM. Pharmacol Res. 2024, 199: 107015. doi: 10.1016/j.phrs.2023.107015. https://doi.org/10.1016/j.phrs.2023.107015 Official Website: http://www.right-statement.org/

Extensions

Our sponsors, supporters and partners